AG
JAZZ icon

Advisor Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Advisor Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$661K Sell
4,437
-318
-7% -$43.3K ﹤0.01% 1479
2019
Q3 		$609K Buy
4,755
+529
+13% +$70.9K ﹤0.01% 1472
2019
Q2 		$602K Buy
4,226
+128
+3% +$17.2K ﹤0.01% 1486
2019
Q1 		$585K Buy
4,098
+343
+9% +$44.7K ﹤0.01% 1477
2018
Q4 		$465K Buy
3,755
+120
+3% +$17.8K ﹤0.01% 1453
2018
Q3 		$611K Buy
3,635
+1,884
+108% +$324K 0.01% 1324
2018
Q2 		$301K Buy
1,751
+851
+95% +$139K ﹤0.01% 1682
2018
Q1 		$136K Buy
900
+153
+20% +$22.4K ﹤0.01% 2285
2017
Q4 		$100K Sell
747
-684
-48% -$94.9K ﹤0.01% 2580
2017
Q3 		$210K Buy
1,431
+550
+62% +$83.2K ﹤0.01% 1813
2017
Q2 		$137K Sell
881
-96
-10% -$14.7K ﹤0.01% 2063
2017
Q1 		$142K Sell
977
-269
-22% -$35K ﹤0.01% 1908
2016
Q4 		$135K Sell
1,246
-10
-0.8% -$1.11K ﹤0.01% 1859
2016
Q3 		$153K Sell
1,256
-82
-6% -$11.1K ﹤0.01% 1713
2016
Q2 		$185K Buy
+1,338
New +$197K ﹤0.01% 1517

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Advisor Group's JAZZ Position: Q4 2019 in Review

Advisor Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 6.7% in Q4 2019, selling an estimated $43.3K and leaving 4,437 shares worth $661K. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Advisor Group first reported a position in JAZZ in Q2 2016 and has held it in 15 quarters since. 446 funds tracked by Wall St. Rank hold JAZZ as of Q4 2019.

  • Advisor Group held 4,437 shares of Jazz Pharmaceuticals worth $661K as of Q4 2019.
  • Advisor Group sold 318 Jazz Pharmaceuticals shares in Q4 2019, an estimated $43.3K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #1479 holding.
  • Advisor Group first reported a position in Jazz Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • 446 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.